Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
Schumer says bill to legalize marijuana Federally will be filed shortly... https://www.marijuanamoment.net/schumer-says-bill-to-legalize-marijuana-federally-will-be-filed-shortly/
WAKE UP OVER HERE... QUIT NAPPING ON THE JOB BOB...
Many people are aware that almost the entire OTC Market has been crashing in unison for the past month or so. Now we may finally know why. On February 18 and February 22, the Market Maker (MM) JANE appeared on 36 of the highest volume stocks in the OTC. Some examples include OZSC, AITX, GAXY, TSNPD, AABB, ENZC, INKW, OPTI, NSAV, PVDG and WDLF. Later that number increased to 78 stocks. February 22 is also the same day that GME and AMC began trending upward again after a dip that lasted for a couple weeks.
Have you ever noticed that many of your big OTC stocks tend to follow the exact same price curves, dips, spikes and dumps at the same time? This manipulation from JANE is why, and based on the timeline of JANE's appearance in these high volume OTC stocks, the evidence suggests that JANE is heavily manipulating the OTC downward using tactics of naked shorting, dark pool selling and Not-Held Orders in some connection with the fight against retail in GME and AMC.
Please check for yourself by going to https://www.otcmarkets.com/otc-link/broker-dealer-directory/JANE and selecting "Common Stock" from the "Type" drop down menu to view the list of stocks that JANE is in. View the historical charts for many of these stocks and watch them follow the same patterns downward beginning February 22nd.”
www.otcmarkets.com
otcmarkets.com
Everybody sleeping?
#SKYE , I FEEL THE NEED FOR SPEED ... LISTEN TO HER HOWL AND ROLL.. CHURNING...
ITS TIME TURN & BURN.. #SKYE RIDE ITS MIGHTY WINGS..GREAT BALLS OF FIRE!!!!!
I need a few more to get to 100K,
This means we all going to add tomorrow.
I know.. I posted it 0.12 is the loading zone if people's got a brain in their head they better be buying... I'm waiting on funds and I will be adding..
8 months ago it was $1, Past three months thre was nothing. NOW its is
The 1 analysts offering 12-month price forecasts for Skye Bioscience Inc have a median target of 2.00, with a high estimate of 2.00 and a low estimate of 2.00. The median estimate represents a +1,500.00% increase from the last price of 0.13.
I thinks nobody knows, this is the point where you buy all the shares you can, GMHO
0.12 support holding like Concrete floor going in... Accumulate is the word of the day.. Because that's what's happening here...
No.. It's trading normally and we might see a pop in April and Skye will continue to trade sideways.. But when you'll see the big move will be the fall of this year... If you look at the 5 year chart you'll see the spikes... Plus many stocks have been beat down including this one I've never seen it trade at 0.03 cents in 6 years the Pandemic really hit the market Hard crushed a lot stocks Creating huge buying opportunity.. I'm lucky I got this at 5 cents loaded up... I've seen SKYE when if you got shares at 14 cents it was a steal because you couldn't get this below 20 cents... I'm telling you since 2014.. I've never seen this stock trade below 12 cents ever... Until the Coronavirus Pandemic 2020.. It seems to be bullish and in recovery mode it may take time...
Could it be competion is keeping this, low? This should be way above this share price.
I would say not many.. Brokers will often tell investors that only stocks above $5 can be sold short. Although this may be true for your particular brokerage firm, it is not a requirement set by the Financial Industry Regulatory Authority (FINRA) or the Securities and Exchange Commission (SEC).. For the few financial institutions that will allow shorting of these stocks below a dollar I'd say there's not many here.. https://www.investopedia.com/ask/answers/03/110703.asp
So how many shorts need to cover before friday on this stock??? Any thoughts?
BEEP BEEP 0.1210 LOADING ZONE!!!!!
Citron once shorted all of Emerald companies w/o much care as to which or why and that really depressed this thing when it had quite a nice run prior. Now that it's on its own this company has value little to no debt or overhang so sky is limit. When is this phase 1 data and Australia development happening. All other stocks in industry are taking part in rally we're still on sidelines.
0.12 is just like when we were trading at 0.03 forever... Then Boom.. Will trade sideways here until news or the company has major positive or the Government has some huge policy change.. When this does truly Break out.. I've seen this play run to 0.50 quick fast and in hurry..
Forecasts has this doubling in value in 6-12 months. I hope this goes up slowly, builds value behind it and stays in a bullish channel. Profit-takers, will always take profits and lawsuits are one reason why. However, this is on my radar and many lists as a sound investment, so I'm in!
Watch for steady climb not, a breakout, this is what we want.
Cheerz
Hey I'm holding... As many years as I been trading this stock this is the 1st time I've ever seen a Litigation ever...
I'm locked and loaded.. Just didn't like seeing that BS litigation breach of fiduciary duty according to the law firm..
This is what the Law firm is Alleging breach of fiduciary duty... https://www.investopedia.com/ask/answers/042915/what-are-some-examples-fiduciary-duty.asp
Give me three hours
Ok I will add again. 100k and above
SKYE is extremely BULLISH on all my lists. Let's see where this goes!
I mean it seems kind of silly... They're saying they believe one of the board members was neglecting their duties.... Their timing is impeccable... Would you agree maybe given some a little more time to accumulate...
Just getting started on there Suspicions...
OR is it a game, before we go UP????
So where are we now, is this OK or not ?
I've been invested with quite a few stocks that have litigation I just don't like it , it's a eye sore... Stocks usually still did well I made money but it was unwanted B.S.
If somebody has a complaint, doesnt mean its true, But I agree, some explaining would we nice
Cant say I'm happy about this.. Out of Nowhere.. https://finance.yahoo.com/news/investigation-alert-fields-kupka-shukurov-131000506.html
Become a mod and access to the ibox and stickies are at hand
Maybe someone that is invested here, should get that IBOX filled in with info. This is now on my watchlist. If I tell my group it has be a professional/verified presentation. If you want the steady volume and price appreciation, you should put info in Ibox and Stickies!
Share structure
Filings links
Company info should do it..
Target is actually .30 in 3 months.
I would like to make that happen, but I cannot move the group participants over here, unless the Ibox has info and the Sticky posts have quick info and company growth filing.
Use their 8-K's 10K's
I've been in tickers that had these legs and we've pushed them all the way up to .60/.90 etc.. From Copper.
The OTC is HOT right now!
Cheerz
https://www.sec.gov/edgar/browse/?CIK=1516551&owner=exclude
Yea this is good play.. I've been watching and trading it for years... This has popped to above 0.50 and dollar multiple times.. The Patience will be rewarded here..
we are moving up faster then you think!
Somebody bought 238,000 SKYE at 0.13... Woooooo BIG SPENDER!!!!! https://ih.advfn.com/stock-market/USOTC/skye-bioscience-qb-SKYE/trades
Well, whatever they said worked. I'll message back if I find a playback.
Thanks
They held an IR presentation this morning
Mar 9, 2021 7:00 am EST
H.C. Wainwright Global Life Sciences Conference
Can't be a delayed reaction to the additional board members. Hopefully something big to come.
What's driving the PPS up? Now 30% on very strong volume
Brilliant idea- to add an "e" to an existing company's name.
I think I'll start a new company
Maybe
The Forde Motor Company?
Applee?
Facebooke?
IMO, it was a really stupid decision to name the company Skye Bioscience when there was already a Sky Bioscience.
https://skyebioscience.com
http://www.skybioscience.com
Skye Bioscience Appoints Cannabinoid Science Experts Giovanni Appendino, PhD and Eduardo Muñoz, MD, PhD to Scientific Advisory Board
Mon, March 8, 2021, 8:39 AM
San Diego, Calif., March 08, 2021 (GLOBE NEWSWIRE) -- Skye Bioscience, Inc. (OTCQB: SKYE) (“SKYE” or the “Company”), a biopharmaceutical company focused on developing proprietary, synthetic cannabinoid-derived molecules to treat glaucoma and other diseases with significant unmet need, announced today the appointment of scientific innovators and cannabinoid experts, Giovanni Appendino, PhD and Eduardo Muñoz, MD, PhD to its scientific advisory board.
“We are honored to welcome two of the world’s most influential thought leaders in cannabinoid science, Drs. Appendino and Muñoz, to our scientific advisory board as we continue to advance our research and deepen our understanding of cannabinoid-based medicines,” said Punit Dhillon, Chief Executive Officer of Skye Bioscience. “Their combined expertise, insights, and experience in developing cannabinoid-derived clinical candidates will be invaluable as we advance and broaden our pipeline.”
Dr. Appendino has researched natural products for over 40 years, leading to the discovery and isolation of over 200 novel compounds, including novel phytocannabinoids and chemistry for cannabinoid-derived molecules. He is a Professor of Organic Chemistry, Department of Pharmaceutical Sciences at the University of Eastern Piedmont, Novara, Italy, where his research activities focus on isolation, chemical modification, and bioactive natural products synthesis. In recognition of his research, he was awarded the Rhône-Poulenc Rorer Award of the Phytochemical Society of Europe in 1991, the Quilico Medal of the Italian Chemical Society in 2009 the Bruker Prize of the Phytochemical Society of Europe in 2014. In 2018, he was elected to the Italian Academy of Sciences for his achievements in chemistry.
Dr. Appendino has authored over 400 peer-reviewed articles, 15 book chapters, and 32 patents on natural products chemistry and bioactivity. He is Editor-in-Chief of the Journal Fitoterapia and editorial board member of the journals Acta Pharmaceutica Sinica B, Pharma Nutrition, Natural Products Research, Chinese Herbal Medicines, and the book series Progress in the Chemistry of Organic Natural Products.
Dr. Muñoz has over 35 years of experience in biomedical research, focused on cannabinoids, pharmacology, and inflammation, providing deep expertise in the mechanism of actions of cannabinoids and the development of new cannabinoid-based chemical entities. He is a Professor of Immunology, Department of Cell Biology, Physiology and Immunology of the University of Córdoba, Spain, and Director of the inflammation and cancer research group at the Institute Maimonides for Biomedical Research Córdoba.
Dr. Muñoz has authored of over 300 articles, book chapters, patents, and is an editorial board member of journals Planta Medica, and Fitoterapia. He is also the co-founder of two biotech companies, VivaCell Biotechnology (now Emerald Biotechnology) and InnoHealth Group (now part of Evonik Industries GmbH).
Dr's. Appendino & Muñoz will serve alongside Skye’s world-class ophthalmology advisory board, comprised of Jeffrey Goldberg, MD, Ph.D., Professor and Chair, Department of Ophthalmology, Byers Eye Institute at Stanford University; Louis Pasquale, MD, FARVO, Professor of Ophthalmology at the Icahn School of Medicine, Chair of the Department of Ophthalmology and Vice-Chair of Translational Ophthalmology Research, Mount Sinai; and Robert Ritch, MD, Shelley, and Steven Einhorn Distinguished Chair, Surgeon Director Emeritus and Chief of Glaucoma Services at the New York Eye & Ear Infirmary of Mount Sinai.
Followers
|
137
|
Posters
|
|
Posts (Today)
|
0
|
Posts (Total)
|
6316
|
Created
|
11/12/14
|
Type
|
Free
|
Moderators |
Our lead candidate, THCVHS, a proprietary prodrug of tetrahydrocannabinol (THC), is a topical formulation under development for the treatment of glaucoma and ocular hypertension (OHT).
Previous US government studies in humans discovered that THC was able to reduce intraocular pressure (IOP), which is in part responsible for the crush-like injury to the cells of the optic nerve that can eventually result in blindness. Additional preclinical studies have shown the potential for THC to also provide neuroprotective benefit, which may be especially important to patients with glaucoma who are experiencing disease progression with normal IOP levels.
One of the major drawbacks of previous studies of the use of THC for glaucoma was that they relied on inhalation or ingestion of THC. These systemic routes of drug administration cause negative side effects like psychotropic effects and potentially decreasing blood pressure , which resulted in the American Academy of Opthamology determining that the adverse effects of systemic cannabis administration/consumption outweighed its therapeutic benefit.
At Skye Bioscience, we chemically modify THC to create a unique synthetic molecule with the intent to safely realize the known positive effects of THC. Our molecule enables enhanced local delivery in the eye, reduced systemic side effects, and the potential for neuroprotection for the treatment of ocular diseases.
Glaucoma is a group of eye diseases that can cause vision loss and blindness by damaging a nerve in the back of the eye called the optic nerve. Damage to the optic nerve is caused by increased intraocular pressure (IOP) due to improper drainage and/or overproduction of fluid in the eye.
According to the American Academy of Ophthalmology, glaucoma affects over 75million people worldwide and is the leading cause of blindness in adults aged 60 and older.
Current therapies can lower IOP but progressive tolerance requires switching or combining drugs. They do NOT provide neuroprotective capabilities.
In preclinical studies, Skye’s THCVHS demonstrated the potential to significantly reduce intraocular pressure (IOP) – exceeding the capabilities of leading commercialized drugs in the current glaucoma market.
Additionally, it has been demonstrated:
We develop novel and proprietary classes of synthetic molecules through the modification of naturally derived systems.
Shifting the solutions paradigm on a effective treatment of diseases through the development of novel neuroprotective solutions.
Science First
The foundation of Skye Bioscience.
Revolutionary Solutions
Solving unmet needs of diseases with limited treatment offerings.
Product-led
Commercial differentiated applications to provide therapeutic benefits.
Impact driven
Change makers. Platform solutions that can extend beyond a single disease.
Mr. Dhillon was the co-founder, CEO, and director of OncoSec Medical Inc., a leading biopharmaceutical company developing cancer immunotherapies for the treatment of solid tumors.
Mr. Diep brings more than 15 years of scientific and clinical research experience to Skye Bioscience. Prior to joining Skye, Mr. Diep was at Protox Therapeutics Inc.
Richard has more than 30 years of business experience and served as a Vice President to CFO on multiple companies in a wide range of industries both public and private, domestic and international.
Mr. Kim serves as the General Counsel and Director of IP at Emerald Bioscience. He is an experienced biotech executive and corporate attorney, and a registered patent attorney.
Karam Takhar serves as Vice President, Corporate Development & Investor Relations at Skye Bioscience Inc. Prior to joining Skye, Mr. Takhar was at Emerald Health Sciences.
Mr. Dhillon was the co-founder, CEO, and director of OncoSec Medical Inc., a leading biopharmaceutical company developing cancer immunotherapies for the treatment of solid tumors.
Mr. Heppell is the co-founder, President and Director of BC Advantage Funds (VCC) Ltd., a venture fund that invests in and builds technology, life science and clean technology companies.
Dr. Dalesandro is the President of Brecon Pharma Consulting, a full-service biotech consultancy firm focused on identifying and obtaining critical information early in product development.
Dr. Muñoz is a Professor of Immunology in the Department of Cell Biology, Physiology, and Immunology of the University of Córdoba, Spain.
Dr. Pasquale is a Professor of Organic Chemistry, Department of Pharmaceutical Sciences at the University of Eastern Piedmont, Novara, Italy, where his research activities focus on isolation ..
Dr. Goldberg is the Professor and Chair of Ophthalmology and Director of the Spencer Center for Vision Research at the Byers Eye Institute at Stanford University.
Dr. Pasquale is the Professor of Ophthalmology at the Icahn School of Medicine at Mount Sinai in New York City.
Dr. Ritch holds the Shelley and Steven Einhorn Distinguished Chair in Ophthalmology and is Clinical Professor of Ophthalmology at the Mt. Sinai Medical School and Surgeon Director Emeritus.
Volume | |
Day Range: | |
Bid Price | |
Ask Price | |
Last Trade Time: |